Richard J Burden1, Noel Pollock, Gregory P Whyte, Toby Richards, Brian Moore, Mark Busbridge, Surjit K Srai, James Otto, Charles R Pedlar. 1. 1Centre for Health, Applied Sport, and Exercise Science, St. Mary's University, Twickenham, UNITED KINGDOM; 2British Athletics, Hospital of St. John and St. Elizabeth, London, UNITED KINGDOM; 3Research Institute for Sport and Exercise Science, Liverpool John Moores University, Liverpool, UNITED KINGDOM; 4Division of Surgery, University College London, London, UNITED KINGDOM; 5ORRECO, Institute of Technology, Sligo, IRELAND; 6Department of Clinical Chemistry, Imperial College Healthcare National Health Service Trust, London, UNITED KINGDOM; and 7Research Department of Structural and Molecular Biology, University College, London, UNITED KINGDOM.
Abstract
PURPOSE: Iron-deficient athletes are often treated with long-term, low-dose iron therapy. Such treatments may be efficacious in correcting iron deficiency; however, the effect on acute and chronic iron metabolism and subsequent endurance capacity is less clear. METHODS:Fifteen national and international standard runners were identified as iron deficient nonanemic (IDNA) and assigned to either an intravenous iron treatment group or placebo group. Participants completed three exercise tests to volitional exhaustion, as follows: before treatment, within 24 h, and 4 wk after treatment. RESULTS:Serum ferritin, serum iron, and transferrin saturation were significantly improved in the iron group after intervention and compared with those in placebo (P < 0.05). Hepcidin levels were significantly greater before and after exercise after the iron injection (P < 0.05), and this was independent of changes in interleukin-6. There were no differences between groups in red cell indices, total hemoglobin mass, V˙O2max, submaximal blood lactate, running economy, RPE, or time to exhaustion (P > 0.05). CONCLUSIONS: A single 500-mg intravenous iron injection is effective for improving iron status for at least 4 wk, but this does not lead to improved aerobic capacity. This investigation suggests that iron availability supersedes inflammation in the regulation of hepcidin in IDNA endurance athletes after acute intravascular iron injection treatment.
RCT Entities:
PURPOSE:Iron-deficient athletes are often treated with long-term, low-dose iron therapy. Such treatments may be efficacious in correcting iron deficiency; however, the effect on acute and chronic iron metabolism and subsequent endurance capacity is less clear. METHODS: Fifteen national and international standard runners were identified as iron deficient nonanemic (IDNA) and assigned to either an intravenous iron treatment group or placebo group. Participants completed three exercise tests to volitional exhaustion, as follows: before treatment, within 24 h, and 4 wk after treatment. RESULTS: Serum ferritin, serum iron, and transferrin saturation were significantly improved in the iron group after intervention and compared with those in placebo (P < 0.05). Hepcidin levels were significantly greater before and after exercise after the iron injection (P < 0.05), and this was independent of changes in interleukin-6. There were no differences between groups in red cell indices, total hemoglobin mass, V˙O2max, submaximal blood lactate, running economy, RPE, or time to exhaustion (P > 0.05). CONCLUSIONS: A single 500-mg intravenous iron injection is effective for improving iron status for at least 4 wk, but this does not lead to improved aerobic capacity. This investigation suggests that iron availability supersedes inflammation in the regulation of hepcidin in IDNA endurance athletes after acute intravascular iron injection treatment.
Authors: Marc Sim; Laura A Garvican-Lewis; Gregory R Cox; Andrew Govus; Alannah K A McKay; Trent Stellingwerff; Peter Peeling Journal: Eur J Appl Physiol Date: 2019-05-04 Impact factor: 3.078
Authors: Anna Skarpańska-Stejnborn; Piotr Basta; Jerzy Trzeciak; Alicja Michalska; M Emin Kafkas; Donata Woitas-Ślubowska Journal: J Int Soc Sports Nutr Date: 2017-02-28 Impact factor: 5.150
Authors: Brett L Houston; Daryl Hurrie; Jeff Graham; Brittany Perija; Emily Rimmer; Rasheda Rabbani; Charles N Bernstein; Alexis F Turgeon; Dean A Fergusson; Donald S Houston; Ahmed M Abou-Setta; Ryan Zarychanski Journal: BMJ Open Date: 2018-04-05 Impact factor: 2.692